New report shows economic incentives are needed to effectively fight antimicrobial resistance

Media Enquiries

Join media list

Press Release

Ottawa, September 08, 2023 – Innovative Medicines Canada (IMC) welcomes the release of the Council of Canadian Academies’ (CCA) report on economic incentives for high-value antimicrobials. The report, coupled with the recent release of the Pan-Canadian Action Plan for Antimicrobial Resistance (AMR Action Plan), provides important building blocks for Canada to address the increasing threat of antimicrobial resistance (AMR) both domestically and globally.

IMC applauds the recommendation in the report for Canada to pursue a subscription pull incentive model and contribute its fair share of funding relative to other high-income countries. Assigning a pull incentive value that is equivalent to Canada’s GDP per capita within the G7 will help revive the global antimicrobial pipeline and improve Canada’s access to new and novel antimicrobials.

The report also acknowledged the importance of other elements, such as Health Technology Assessment evaluation and regulatory review, in Canada’s fight against AMR.

“To ensure Canadians will have access to new antimicrobials when they need them, federal, provincial and territorial governments must work together with the innovative pharmaceutical industry to determine the appropriate design and implementation of a made-in-Canada pull incentive,” said Pamela Fralick, President of Innovative Medicines Canada.

IMC encourages the Government of Canada to implement the recommendations in the CCA report and calls on the Government to announce funding tied to the implementation of the AMR Action Plan.

About Innovative Medicines Canada

Innovative Medicines Canada is the national association representing the voice of Canada’s innovative pharmaceutical industry. The association advocates for policies that enable the discovery, development, and delivery of innovative medicines and vaccines to improve the lives of all Canadians and supports the members’ commitment to being a valued partner in the Canadian healthcare system. The association represents 49 companies that invest nearly $1.4 billion in R&D annually, fueling Canada’s knowledge-based economy, while contributing $8 billion to Canada’s economy. Guided by the Code of Ethical Practices, all members work with governments, private payers, healthcare professionals, and stakeholders in a highly ethical manner.

– 30 –

For further information:

Marise Varanda
Director, Media Relations & Content
Telephone: 613-462-5367


Discover. Learn.

Informative content to keep you up to date on the most pressing issues facing our industry.